## Human TNFRSF17 / BCMA / CD269 Protein (His & Fc Tag) (HPLC-verified)

Catalog Number: HPLC-10620-H03H



#### **General Information**

Gene Name Synonym:

BCM; BCMA; CD269; TNFRSF13A

**Protein Construction:** 

A DNA sequence encoding the extracellular domain of human TNFRSF17 (NP\_001183.2) (Met 1-Ala 54) was fused with the C-terminal polyhistidine-tagged Fc region of human IgG1 at the C-terminus and a signal peptide at the N-terminus.

Source: Human

Expression Host: HEK293 Cells

**QC** Testing

Purity: > 95 % as determined by SDS-PAGE.

> 95 % as determined by SEC-HPLC.

**Endotoxin:** 

 $< 1.0 \; EU \; per \; \mu g$  of the protein as determined by the LAL method

Predicted N terminal: Met 1

**Molecular Mass:** 

The recombinant human TNFRSF17/Fc is a disulfide-linked homodimer. The reduced monomer comprises 302 amino acids after removal of the signal peptide and has a predicted molecular mass of 34 kDa. As a result of glycosylation, the apparent molecular mass of rh TNFRSF17/Fc monomer is approximately 40 kDa in SDS-PAGE under reducing conditions.

#### Formulation:

Lyophilized from sterile PBS, pH 7.4.

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

#### **Usage Guide**

#### Stability & Storage:

Samples are stable for twelve months from date of receipt at -20  $^{\circ}$ C to -80  $^{\circ}$ C.

Store it under sterile conditions at -20°C to -80°C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

#### Reconstitution:

Detailed reconstitution instructions are sent along with the products.

### **Protein Description**

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cellsurface BCMA may contribute directly to tumor rejection in vivo.

#### References


1.Novak AJ, et al. (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 103 (2): 689–94. 2.O'Connor BP, et al. (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 199(1): 91-8. 3.Moser K, et al. (2006) Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol. 18(3): 265-70.


# Human TNFRSF17 / BCMA / CD269 Protein (His & Fc Tag) (HPLC-verified)





SDS-PAGE: SEC-HPLC:





96.3% as determined by SDS-PAGE

98.9% as determined by SEC-HPLC Analysis